Mind Medicine (MindMed) Inc. (MNMD) Stock Analysis & Investment Frameworks
Mind Medicine (MindMed) Inc. (MNMD) stock analysis on Invetso. Review Mind Medicine (MindMed) Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Mind Medicine (MindMed) Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
Mind Medicine (MindMed) Inc. Key Financial Metrics
- Market Cap: $1.56B
- Revenue: $N/A
- ROE: -85.23%
- ROIC: -23.81%
- Dividend Yield: N/A
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for managing opioid withdrawal. The company's portfolio also includes MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the core symptoms associated with autism spectrum disorder. Its corporate headquarters are situated in Vancouver, Canada.